Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

by

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.

​The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s. 

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.